| Steven Deroche, CRNA | |
|
1450 Western Ave, Suite 102, Albany, NY 12203-3539 | |
| (518) 463-0050 | |
| (518) 207-2973 |
| Full Name | Steven Deroche |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 3 Years |
| Location | 1450 Western Ave, Albany, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215695812 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 627880 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Peter's Hospital | Albany, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Group Of Albany, Pc | 5092602458 | 95 |
News Archive
The Federation of American Societies for Experimental Biology (FASEB) has launched a web-based portal that brings together information on a wide range of programs aimed at increasing the diversity of the biomedical workforce. The FASEB and FASEB Society Resources for Underrepresented Minority Students and Scientists webpage highlights over 50 unique initiatives offered by FASEB and its member societies.
Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has entered into an exclusive agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), to market the authorized generic version of Concerta® (methylphenidate hydrochloride extended-release tablets). Watson will launch its authorized generic of Concerta on May 1, 2011. Concerta is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).
Senesco Technologies, Inc. has, on March 26, 2010, entered into definitive agreements with institutional and accredited investors for a private placement of up to 11,497 shares of Convertible Preferred Stock of the Company and Warrants to purchase up to 35,928,125 shares of Common Stock for a gross purchase price of approximately $11,497,000.
Living longer with obesity can lead to both longer hospital stays and more avoidable trips to the hospital, according to two new studies from Purdue University.
Gentium S.p.A. has announced top-line results from a historically controlled, multicenter, open label, Phase III trial designed to evaluate the safety and efficacy of 25 mg/kg/day of Defibrotide for the treatment of severe veno-occlusive disease (sVOD) in hematopoietic stem cell transplant (SCT) patients.
› Verified 6 days ago
| Entity Name | Anesthesia Group Of Albany, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598700379 PECOS PAC ID: 5092602458 Enrollment ID: O20040301000885 |
News Archive
The Federation of American Societies for Experimental Biology (FASEB) has launched a web-based portal that brings together information on a wide range of programs aimed at increasing the diversity of the biomedical workforce. The FASEB and FASEB Society Resources for Underrepresented Minority Students and Scientists webpage highlights over 50 unique initiatives offered by FASEB and its member societies.
Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has entered into an exclusive agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), to market the authorized generic version of Concerta® (methylphenidate hydrochloride extended-release tablets). Watson will launch its authorized generic of Concerta on May 1, 2011. Concerta is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).
Senesco Technologies, Inc. has, on March 26, 2010, entered into definitive agreements with institutional and accredited investors for a private placement of up to 11,497 shares of Convertible Preferred Stock of the Company and Warrants to purchase up to 35,928,125 shares of Common Stock for a gross purchase price of approximately $11,497,000.
Living longer with obesity can lead to both longer hospital stays and more avoidable trips to the hospital, according to two new studies from Purdue University.
Gentium S.p.A. has announced top-line results from a historically controlled, multicenter, open label, Phase III trial designed to evaluate the safety and efficacy of 25 mg/kg/day of Defibrotide for the treatment of severe veno-occlusive disease (sVOD) in hematopoietic stem cell transplant (SCT) patients.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Steven Deroche, CRNA 1450 Western Ave, Suite 102, Albany, NY 12203-3539 Ph: (518) 463-0050 | Steven Deroche, CRNA 1450 Western Ave, Suite 102, Albany, NY 12203-3539 Ph: (518) 463-0050 |
News Archive
The Federation of American Societies for Experimental Biology (FASEB) has launched a web-based portal that brings together information on a wide range of programs aimed at increasing the diversity of the biomedical workforce. The FASEB and FASEB Society Resources for Underrepresented Minority Students and Scientists webpage highlights over 50 unique initiatives offered by FASEB and its member societies.
Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has entered into an exclusive agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), to market the authorized generic version of Concerta® (methylphenidate hydrochloride extended-release tablets). Watson will launch its authorized generic of Concerta on May 1, 2011. Concerta is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).
Senesco Technologies, Inc. has, on March 26, 2010, entered into definitive agreements with institutional and accredited investors for a private placement of up to 11,497 shares of Convertible Preferred Stock of the Company and Warrants to purchase up to 35,928,125 shares of Common Stock for a gross purchase price of approximately $11,497,000.
Living longer with obesity can lead to both longer hospital stays and more avoidable trips to the hospital, according to two new studies from Purdue University.
Gentium S.p.A. has announced top-line results from a historically controlled, multicenter, open label, Phase III trial designed to evaluate the safety and efficacy of 25 mg/kg/day of Defibrotide for the treatment of severe veno-occlusive disease (sVOD) in hematopoietic stem cell transplant (SCT) patients.
› Verified 6 days ago
William D Beighey, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1450 Western Ave Ste 102, Anesthesia Group Of Albany, Pc, Albany, NY 12203 Phone: 518-463-0050 Fax: 518-207-2793 | |
Cathleen R. Motta, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1450 Western Ave Ste 102, Anesthesia Group Of Albany, Pc, Albany, NY 12203 Phone: 518-463-0050 Fax: 518-207-2973 | |
Vincent J Battuello, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1450 Western Ave Ste 102, Anesthesia Group Of Albany, Pc, Albany, NY 12203 Phone: 518-463-0050 Fax: 518-207-2973 | |
Anne D. Gaughan, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1450 Western Ave Ste 102, Anesthesia Group Of Albany, Pc, Albany, NY 12203 Phone: 518-463-0050 Fax: 518-207-2973 | |
Christine M Piraino, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1450 Western Ave Ste 102, Anesthesia Group Of Albany, Pc, Albany, NY 12203 Phone: 518-463-0050 Fax: 518-207-2973 | |
Hiesook Sacca, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1450 Western Ave Ste 102, Anesthesia Group Of Albany Pc, Albany, NY 12203 Phone: 518-463-0050 Fax: 518-207-2973 | |
Rachel Dubay, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1450 Western Ave, Suite 102, Albany, NY 12203 Phone: 518-463-0050 |